πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 8062640

High affinity human antibodies to PCSK9

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8048418

Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and V

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 27 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8043617

Human antibodies to human IL-6 receptor

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Oct 25 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 20 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8029791

Modified chimeric polypeptides with improved pharmacokinetic properties

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Oct 04 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8003103

High affinity human antibodies to human IL-18 receptor

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 23 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 18 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7988967

High affinity human antibodies to human nerve growth factor

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 02 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 28 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7972598

VEGF-binding fusion proteins and therapeutic uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 05 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 30 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7964377

Nucleic acid molecule encoding a fusion polypeptide capable of binding VEGF

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 21 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 16 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7927583

Receptor based antagonists and methods of making and using

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 19 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 14 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7919593

Human antibodies to human delta like ligand 4

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 05 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7879984

Human antibodies to human CD20 and method of using thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 27 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7837999

Method of increasing muscle mass with IGF-1 fusion polypeptides

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 23 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 18 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7820154

Use of IL-1 antagonists to treat gout

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Oct 26 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 21 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7807164

Lyophilized VEGF antagonist formulations for intravitreal administration

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Oct 05 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 30 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7794717

High affinity human antibodies to human IL-4 receptor

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 14 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 09 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7781404

IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 24 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 19 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7732167

Interferon-Ξ±/Ξ² binding fusion proteins and therapeutic uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 08 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 03 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7704500

Methods of inhibiting ascites formation with modified chimeric VEGF polypeptides

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 27 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 22 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7655758

Stable liquid IL-1 antagonist formulations

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 02 2010 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 28 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7635474

VEGF-binding fusion proteins

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 22 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 17 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7632503

Method of treating a muscle-related condition with modified IGF1 polypeptides

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 15 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 10 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7632490

Use of IL-1 antagonists to treat gout

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 15 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 10 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7615220

High affinity human antibodies to human IL-18 receptor

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 10 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 05 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7608261

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Oct 27 2009 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted